Influence of initial treatment delay on overall survival and event-free survival in childhood acute lymphoblastic leukemia

Main Article Content

Irenne Purnama
Pudjo Hagung Widjajanto
Wahyu Damayanti

Abstract

Background Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Initial treatment delay is a modifiable prognostic factor that significantly affects overall survival (OS) and event-free survival (EFS) of childhood ALL in high-income countries. Nevertheless, the effect of delayed initial treatment in low-middle income countries had not been determined.


Objective To analyze relationships between initial treatment delay with overall survival and event-free survival in children with ALL.


Methods A retrospective study was conducted in children aged < 18 years newly diagnosed with ALL L1 and L2 from January 2013 until December 2018 at Dr. Sardjito Hospital, Yogyakarta. Initial treatment delay was defined as a time interval of more than 3 days between diagnosis and treatment. The outcomes of the study were OS and EFS. Negative events were defined as remission failure, relapse, dropping out, and death. Overall survival (OS) and event free survival (EFS) were analyzed by Kaplan-Meier and log-rank tests.


Results Of 341 subjects, 188 (55.5%) underwent delayed initial treatment. There were no significant relationships between initial treatment delay and OS (HR 0.845; 95%CI 0.548 to 1.302; P=0.445) or EFS (HR=0.937; 95%CI 0.689 to 1.275; P=0.971). Multivariate analysis revealed that age was an independent prognostic factor for both OS (P<0.001) and EFS
(P<0.001).


Conclusion Initial treatment delay is not associated with OS or EFS.  Age is an independent predictor for both OS and EFS.

Article Details

How to Cite
1.
Purnama I, Widjajanto P, Damayanti W. Influence of initial treatment delay on overall survival and event-free survival in childhood acute lymphoblastic leukemia. PI [Internet]. 23Aug.2021 [cited 23Sep.2021];61(4):217-2. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/2445
Section
Pediatric Hemato-Oncology
Received 2020-07-09
Accepted 2021-08-23
Published 2021-08-23

References

1. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64:83–103. DOI: 10.3322/caac.21219.
2. Supriyadi E, Widjajanto PH, Purwanto I, Cloos J, Veerman AJP, Sutaryo S. Incidence of childhood leukemia in Yogyakarta, Indonesia, 1998-2009. Pediatr Blood Cancer. 2011;57:588–93. DOI: 10.1002/pbc.23109.
3. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30:1663–9. DOI: 10.1200/JCO.2011.37.8018.
4. Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Artic Lancet Haematol. 2017;4:202–19. DOI: 10.1016/s2352-3026(17)30052-2.
5. Wijayanti LP, Eddy S. Faktor Prognostik dan Kesintasan Pasien Pasien leukemia limfoblastik akut anak di RSUP Dr. Sardjito, Yogyakarta, 2010–2015. Indones J Cancer. 2017;11:145–50. DOI: 10.33371/ijoc.v11i4.532.
6. Magrath I, Shanta V, Advani S, Adde M, Arya LS, Banavali S, et al. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year peroid. Eur J Cancer. 2005;41:1570–83. DOI: 10.1016/j.ejca.2004.11.004.
7. Baker JM, To T, Beyene J, Zagorski B, Greenberg ML, Sung L. Influence of length of time to diagnosis and treatment on the survival of children with acute lymphoblastic leukemia: A population-based study. Leuk Res. 2014;38:204-9. DOI: 10.1016/j.leukres.2013.11.014.
8. Yeoh AEJ, Tan D, Li C, Hori H, Tse E, Pui C. Management of adult and paediatric acute lymphoblastic leukaemia in Asia : resource-stratifi ed guidelines from the Asian Oncology Summit 2013. Lancet Oncol. 2018;14:e508–23. DOI: 10.1016/S1470-2045(13)70452-2.
9. Wahl SK, Gildengorin G, Feusner J. Weekend delay in initiation of chemotherapy for acute lymphoblastic leukemia. J Pediatr Hematol/Oncol. 2012;34:e8–11. DOI: 10.1097/MPH.0b013e31822e9c0b.
10. Brunton L, Hilal-Dandan R, Bjorn K. The pharmacological basis of therapeutics. 13th edition. New York: Mc Graw Hill; 2018. p.1162.